Zobrazeno 1 - 3 of 3 pro vyhledávání: '"Ángel Nuñez Buiza"'
1
Akademický článek
Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB2 harmonization project comparing three NGS panels
Autor: Fernando López-Ríos, Luis Paz-Ares, Pilar Garrido, Eva M Garrido-Martin, Jose Palacios, Elena Sanchez, Ana Belén Enguita, Javier Ramos-Paradas, Susana Hernández-Prieto, David Lora, Aranzazu Rosado, Tamara Caniego-Casas, Nuria Carrizo, María Teresa Muñoz-Jimenez, Borja Rodriguez, Urbicio Perez-Gonzalez, David Gómez-Sánchez, Irene Ferrer, Santiago Ponce Aix, Ángel Nuñez Buiza
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Background Tumor mutational burden (TMB) is a recently proposed predictive biomarker for immunotherapy in solid tumors, including non-small cell lung cancer (NSCLC). Available assays for TMB determination differ in horizontal coverage, gene content a
Externí odkaz: https://doaj.org/article/a0e4de9a317e425992c6330eeb6a0581
Zobrazit plný text záznamu
2
Akademický článek
CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts
Autor: Anaïs Jiménez-Reinoso, Magdalena Molero-Abraham, Cristina Cirauqui, Belén Blanco, Eva M. Garrido-Martin, Daniel Nehme-Álvarez, Carmen Domínguez-Alonso, Ángel Ramírez-Fernández, Laura Díez-Alonso, Ángel Nuñez-Buiza, África González-Murillo, Raquel Tobes, Eduardo Pareja, Manuel Ramírez-Orellana, José Luis Rodriguez-Peralto, Irene Ferrer, Jon Zugazagoitia, Luis Paz-Ares, Luis Álvarez-Vallina
Publikováno v: OncoImmunology, Vol 13, Iss 1 (2024)
Adoptive transfer of tumor-infiltrating lymphocytes (TIL) has shown remarkable results in melanoma, but only modest clinical benefits in other cancers, even after TIL have been genetically modified to improve their tumor homing, cytotoxic potential o
Externí odkaz: https://doaj.org/article/e8672f59553649e1a19d8ee020cd28b0
Zobrazit plný text záznamu
3
Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB2 harmonization project comparing three NGS panels
Autor: Pilar Garrido, Ana Belén Enguita, Aranzazu Rosado, Javier Ramos-Paradas, Santiago Ponce Aix, Ángel Nuñez Buiza, Susana Hernández-Prieto, Borja Rodriguez, María Teresa Muñoz-Jimenez, Irene Ferrer, David Gomez-Sanchez, Fernando Lopez-Rios, Nuria Carrizo, Tamara Caniego-Casas, Elena Sanchez, David Lora, Luis Paz-Ares, José Palacios, Urbicio Perez-Gonzalez, Eva M. Garrido-Martin
Publikováno v: Journal for ImmunoTherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for Immunotherapy of Cancer
BackgroundTumor mutational burden (TMB) is a recently proposed predictive biomarker for immunotherapy in solid tumors, including non-small cell lung cancer (NSCLC). Available assays for TMB determination differ in horizontal coverage, gene content an
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57e9f1bb4e4226ed21205da64a151aa6
https://doi.org/10.1136/jitc-2020-001904
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje